IFNA1 and COVID-19: While immune characterization of the severe COVID-19 patients is now quite precise, notably dysregulated responses with a strong inflammation and a defect of IFN response (36, 37), a few immunologic studies on predictive factors of the clinical outcome and drug selection have been made (38, 39).